A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. - Wikidata - wikimedia - TriplyDB

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

http://www.wikidata.org/entity/Q33401450

about

The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.8‑bromo‑7‑methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin‑sensitive and resistant ovarian cancer cells Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.Therapeutic targets and new directions for antibodies developed for ovarian cancer.The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Everolimus in colorectal cancer.Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.Cytotoxic enhancement of hexapeptide-conjugated micelles in EGFR high-expressed cancer cells.Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.Casticin induces ovarian cancer cell apoptosis by repressing FoxM1 through the activation of FOXO3a.PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies

P2860

Q26851852-6D6F8816-5634-43A6-A44B-3CC5218695ED Q33921891-CF1908A8-2653-4F95-A05F-130856D79A55 Q36089926-20154828-977B-4C39-803B-4080437672AC Q36635273-CAD0B19B-726C-48B0-AFD9-8BFB40859396 Q37268981-FE7B5A31-778B-4DD6-82F4-EB84D0238EEF Q37397674-CE95AA15-A6AF-4318-9715-09B297B3240C Q37631697-B7F2E7F8-24F5-4BB4-919A-C2993F4BB5AE Q38081233-93636A7E-2231-4CA5-981D-DD6218D4CE3C Q38094782-1337A7FF-D329-4F5D-98B3-C9C6F0AC0BD6 Q38236320-DACCFB9C-E9ED-46A9-A470-D4373C2D521D Q38982625-49030434-2B23-48FD-8621-FDAA44C64312 Q39129968-602E5DF7-3CB2-4983-B945-E5CC5636F003 Q41998858-117FA1A0-8F5C-4DCC-8E9C-3D5A3411C339 Q43300329-B14200DA-3570-4D07-9E5E-4E7DCE43705E Q58790039-719B4AEA-E093-45A4-9701-44CFC7B34DD1

P2860

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

http://www.wikidata.org/entity/Q33401450

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

@ast

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

@en

type

label

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

@ast

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

@en

prefLabel

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

@ast

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

@en

P1433

Q33401450-94BF6705-84A8-4F80-9C01-ED6C6521DDE3

P1476

Q33401450-D7E8E651-A339-4AE3-AAF5-6F6AB335E04F

P2093

Q33401450-132E1514-EA7C-4BC1-ADC6-BA45A21762A5

Q33401450-27E85BEE-AB95-4E59-8604-09AF68695939

Q33401450-2C79D606-E52E-4C9F-8FDD-8F220274F94E

Q33401450-33FF0E4F-A231-40DB-8914-BF96806F6096

Q33401450-3A1023F6-6EC0-461D-AAFC-AEDB466CAA05

Q33401450-3C4EF546-E568-4C2C-A103-DC17D8C6D8CE

Q33401450-3DC3C446-AD82-4362-BFFE-D9FA49AFE9EA

Q33401450-42E46D47-AA02-495D-B0BB-87E3A1E96571

Q33401450-78097AF7-0B84-4BF3-9788-9E2B665FBBEA

Q33401450-83B9D34B-E6E5-4D14-A9DD-76D51EB7E61F

P2860

Q33401450-07F9E0FE-19FC-4DC9-98D0-1A37059BDE07

Q33401450-0B998079-5BF7-4CAE-A1A5-6658F2B28573

Q33401450-1809D6BC-4F12-4200-91C2-19261CA14EA4

Q33401450-18530FAB-6665-443F-A530-F7318CB7F6EB

Q33401450-221F6B55-F014-495E-9BAF-57DE878E2BE2

Q33401450-248CEEBF-7A20-4BE6-B2DA-12B5AE30A702

Q33401450-2F834D66-CFB6-4966-B4A4-D358FF243A4B

Q33401450-3135976D-2C57-4762-B134-FEC5BEF641F9

Q33401450-3C3CD5E2-0C60-4176-80B1-E17E10F00D92

Q33401450-427B7C31-2697-4E5D-B2FF-E15A8ECD99D1

P2888

Q33401450-F90EBF11-3528-46A7-BEDA-765A4C568FC7

P304

Q33401450-B92141BB-1BD7-4E83-A97B-3C5F8B5C4DFA

P31

Q33401450-89B24DCE-9109-46B5-B160-D8F0870CBDD3

P356

Q33401450-3CF3973B-8AE6-42D3-901D-7D3695DE18FB

P433

Q33401450-B7B8FF07-4CF8-48AA-8DE8-31B47BC90F55

P478

Q33401450-49D085B8-9813-4BA9-B1DD-0EC8AD627BDB

P577

Q33401450-E4B8C870-0F77-40F3-A90E-868D12E183CE

P6179

Q33401450-4BE23E4E-0DF5-42A6-A34F-2E345B64F5E0

P698

Q33401450-5A61D469-302D-46EE-8DD2-63D66E533CF3

P921

Q33401450-0C7BAC6D-5051-45C2-8F24-97B5A98D537B

P932

Q33401450-115D84A4-8915-483B-8955-9F75D4317226

P356

S00280-012-1889-8

P1433

Cancer Chemotherapy and Pharmacology

P1476

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

@en

P2093

Alexander N Starodub

http://www.w3.org/2001/XMLSchema#string

Angeles Alvarez-Secord

http://www.w3.org/2001/XMLSchema#string

Elizabeth L Anderson

http://www.w3.org/2001/XMLSchema#string

Gerard C Blobe

http://www.w3.org/2001/XMLSchema#string

Gordana Vlahovic

http://www.w3.org/2001/XMLSchema#string

Herbert I Hurwitz

http://www.w3.org/2001/XMLSchema#string

Hope E Uronis

http://www.w3.org/2001/XMLSchema#string

Johanna C Bendell

http://www.w3.org/2001/XMLSchema#string

Jon Gockerman

http://www.w3.org/2001/XMLSchema#string

Kellen L Meadows

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

Targeting the mTOR signaling network for cancer therapy

The biology of VEGF and its receptors

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

Defining the role of mTOR in cancer

Tumor angiogenesis

EGFR antagonists in cancer treatment

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

P2888

s00280-012-1889-8

P304

95-102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-012-1889-8

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014306924

http://www.w3.org/2001/XMLSchema#string

P698

22638798

http://www.w3.org/2001/XMLSchema#string

P921

P932

4086794

http://www.w3.org/2001/XMLSchema#string